共 10 条
- [1] Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab[J]. BLOOD, 2019, 133 (19) : 2031 - 2042Byrd, John C.Hillmen, PeterO'Brien, SusanBarrientos, Jacqueline C.Reddy, Nishitha M.Coutre, StevenTam, Constantine S.Mulligan, Stephen P.Jaeger, UlrichBarr, Paul M.Furman, Richard R.Kipps, Thomas J.Thornton, PatrickMoreno, CarolMontillo, MarcoPagel, John M.Burger, Jan A.Woyach, Jennifer A.Dai, SandraVezan, RemusJames, Danelle F.Brown, Jennifer R.
- [2] Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial[J]. LANCET ONCOLOGY, 2018, 19 (09) : 1215 - 1228Cramer, Paulavon Tresckow, JuliaBahlo, JasminRobrecht, SandraLangerbeins, PetraAl-Sawaf, OthmanEngelke, AnjaFink, Anna-MariaFischer, KirstenTausch, EugenSeiler, Tillvon Weikersthal, Ludwig FischerHebart, HolgerKreuzer, Karl-AntonBoettcher, SebastianRitgen, MatthiasKneba, MichaelWendtner, Clemens-MartinStilgenbauer, StephanEichhorst, BarbaraHallek, Michael
- [3] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial[J]. LANCET ONCOLOGY, 2016, 17 (07) : 928 - 942Eichhorst, BarbaraFink, Anna-MariaBahlo, JasminBusch, RaymondeKovacs, GaborMaurer, ChristianLange, ElisabethKoeppler, HubertKiehl, MichaelSoekler, MartinSchlag, RudolfVehling-Kaiser, UrsulaKoechling, GeorgPloeger, ChristophGregor, MichaelPlesner, TorbenTrneny, MarekFischer, KirstenDoehner, HarmutKneba, MichaelWendtner, Clemens-MartinKlapper, WolframKreuzer, Karl-AntonStilgenbauer, StephanBoettcher, SebastianHallek, Michael
- [4] Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (23) : 2225 - 2236Fischer, K.Al-Sawaf, O.Bahlo, J.Fink, A. -M.Tandon, M.Dixon, M.Robrecht, S.Warburton, S.Humphrey, K.Samoylova, O.Liberati, A. M.Pinilla-Ibarz, J.Opat, S.Sivcheva, L.Du, K. LeFogliatto, L. M.Niemann, C. U.Weinkove, R.Robinson, S.Kipps, T. J.Boettcher, S.Tausch, E.Humerickhouse, R.Eichhorst, B.Wendtner, C. -M.Langerak, A. W.Kreuzer, K. -A.Ritgen, M.Goede, V.Stilgenbauer, S.Mobasher, M.Hallek, M.
- [5] Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial[J]. LANCET HAEMATOLOGY, 2019, 6 (09): : E470 - E479Michallet, Anne-SophieDilhuydy, Marie-SarahSubtil, FabienRouille, ValerieMahe, BeatriceLaribi, KamelVillemagne, BrunoSalles, GillesTournilhac, OlivierDelmer, AlainPortois, ChristellePegourie, BrigitteLeblond, VeroniqueTomowiak, Cecilede Guibert, SophieOrsini, FrederiqueBanos, AnneCarassou, PhilippeCartron, GuillaumeFornecker, Luc MathieuYsebaert, LoicDartigeas, CarolineGraczyk, Malgorzata TruchanVilque, Jean P.Aurran, ThereseCymbalista, FlorenceLepretre, StephaneLevy, VincentFlorence Nguyen-KhacLe Garff-Tavernier, MagaliAanei, CarmenTicchioni, MichelLetestu, RemiFeugier, Pierre
- [6] Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia[J]. BLOOD, 2015, 126 (16) : 1921 - 1924Rossi, DavideTerzi-di-Bergamo, LodovicoDe Paoli, LorenzoCerri, MichaelaGhilardi, GuidoChiarenza, AnnalisaBulian, PietroVisco, CarloMauro, Francesca R.Morabito, FortunatoCortelezzi, AgostinoZaja, FrancescoForconi, FrancescoLaurenti, LucaDel Giudice, IlariaGentile, MassimoVincelli, IolandaMotta, MarinaCoscia, MartaRigolin, Gian MatteoTedeschi, AlessandraNeri, AntoninoMarasca, RobertoPerbellini, OmarMoreno, CarolDel Poeta, GiovanniMassaia, MassimoZinzani, Pier LuigiMontillo, MarcoCuneo, AntonioGattei, ValterFoa, RobinGaidano, Gianluca
- [7] A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRM Cancer Research Group (E1912)[J]. BLOOD, 2018, 132Shanafelt, Tait D.Wang, VictoriaKay, Neil E.Hanson, Curtis A.O'Brien, Susan M.Barrientos, Jacqueline C.Erba, Harry P.Stone, Richard M.Litzow, Mark R.Tallman, Martin S.
- [8] Resistance to ABT-199 induced by microenvironmental signals in chronic iymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors[J]. HAEMATOLOGICA, 2015, 100 (08) : E302 - E306Thijssen, RachelSlinger, ErikWeller, KatinkaGeest, Christian R.Beaumont, Timvan Oers, Marinus H. J.Kater, Arnon P.Eldering, Eric
- [9] Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies[J]. CANCER IMMUNOLOGY RESEARCH, 2018, 6 (10) : 1150 - 1160VanDerMeid, Karl R.Elliott, Michael R.Baran, Andrea M.Barr, Paul M.Chu, Charles C.Zent, Clive S.
- [10] Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) : 2517 - 2528Woyach, J. A.Ruppert, A. S.Heerema, N. A.Zhao, W.Booth, A. M.Ding, W.Bartlett, N. L.Brander, D. M.Barr, P. M.Rogers, K. A.Parikh, S. A.Coutre, S.Hurria, A.Brown, J. R.Lozanski, G.Blachly, J. S.Ozer, H. G.Major-Elechi, B.Fruth, B.Nattam, S.Larson, R. A.Erba, H.Litzow, M.Owen, C.Kuzma, C.Abramson, J. S.Little, R. F.Smith, S. E.Stone, R. M.Mandrekar, S. J.Byrd, J. C.